Shinichiro Akichika

Dr. Shinichiro Akichika

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2019 in Science
Verified
Journal Article
Closed access
PDF file
SAShinichiro Akichika
Shinichiro Akichika
SHSeiichi Hirano
Seiichi Hirano
YSYuichi Shichino
Yuichi Shichino
TSTakeo Suzuki
Takeo Suzuki
HNHiroshi Nishimasu
Hiroshi Nishimasu
TSTsutomu Suzuki
Tsutomu Suzuki
A cap-specific m 6 A writer: N 6 ,2′- O -dimethyladenosine (m 6 Am) is present at the transcription start nucleotide of capped mRNAs in vertebrates. Akichika et al. quantified the abundance of this modification in the transcriptome and identified the writer protein, cap-specific adenosine methyltransferase (CAPAM), needed for this modification. CAPAM contains a unique structure that recognizes cap-specific N 6 -methyladenosine (m 6 A) as the substrate. The protein interacts with RNA polymerase II, suggesting that the modification occurs cotranscriptionally. The m 6 Am promotes the translation of capped mRNAs in a eIF4E-independent fashion. Science , this issue p. eaav0080

5 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMayuko Takakura
Mayuko Takakura
KIKensuke Ishiguro
Kensuke Ishiguro
SAShinichiro Akichika
Shinichiro Akichika
KMKenjyo Miyauchi
Kenjyo Miyauchi
TSTsutomu Suzuki
Tsutomu Suzuki
Transfer (t)RNAs contain a wide variety of post-transcriptional modifications, which play critical roles in tRNA stability and functions. 3-(3-amino-3-carboxypropyl)uridine (acp3U) is a highly conserved modification found in variable- and D-loops of tRNAs. Biogenesis and functions of acp3U have not been extensively investigated. Using a reverse-genetic approach supported by comparative genomics, we find here that the Escherichia coli yfiP gene, which we rename tapT (tRNA aminocarboxypropyltransferase), is responsible for acp3U formation in tRNA. Recombinant TapT synthesizes acp3U at position 47 of tRNAs in the presence of S-adenosylmethionine. Biochemical experiments reveal that acp3U47 confers thermal stability on tRNA. Curiously, the ΔtapT strain exhibits genome instability under continuous heat stress. We also find that the human homologs of tapT, DTWD1 and DTWD2, are responsible for acp3U formation at positions 20 and 20a of tRNAs, respectively. Double knockout cells of DTWD1 and DTWD2 exhibit growth retardation, indicating that acp3U is physiologically important in mammals.

2 October 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
JMJin Matsuura
Jin Matsuura
SAShinichiro Akichika
Shinichiro Akichika
FWFan-Yan Wei
Fan-Yan Wei
TSTsutomu Suzuki
Tsutomu Suzuki
TYTakahiro Yamamoto
Takahiro Yamamoto
TCTakeshi Chujo
Takeshi Chujo
Human cytoplasmic tRNAs contain dihydrouridine modifications at positions 16 and 17 (D16/D17). The enzyme responsible for D16/D17 formation and its cellular roles remain elusive. Here, we identify DUS1L as the human tRNA D16/D17 writer. DUS1L knockout in the glioblastoma cell lines LNZ308 and U87 causes loss of D16/D17. D formation is reconstituted in vitro using recombinant DUS1L in the presence of NADPH or NADH. DUS1L knockout/overexpression in LNZ308 cells shows that DUS1L supports cell growth. Moreover, higher DUS1L expression in glioma patients is associated with poorer prognosis. Upon vector-mediated DUS1L overexpression in LNZ308 cells, 5′ and 3′ processing of precursor tRNATyr(GUA) is inhibited, resulting in a reduced mature tRNATyr(GUA) level, reduced translation of the tyrosine codons UAC and UAU, and reduced translational readthrough of the near-cognate stop codons UAA and UAG. Moreover, DUS1L overexpression increases the amounts of several D16/D17-containing tRNAs and total cellular translation. Our study identifies a human dihydrouridine writer, providing the foundation to study its roles in health and disease.

5 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
RKRyoya Kano
Ryoya Kano
COChihiro Oyama
Chihiro Oyama
CIChihiro Ikeda
Chihiro Ikeda
AIAkiko Inujima
Akiko Inujima
KKKeiichi Koizumi
Keiichi Koizumi
YHYutaka Hirose
Yutaka Hirose
PCIF1 is primarily recognized as an RNA methyltransferase that mediates N6-methylation of cap-proximal adenosine (m6Am) and plays diverse roles in gene expression. In this study, we uncover a novel role for PCIF1 as a crucial negative regulator of type I interferon (IFN) induction, a pathway critical for antiviral immunity whose dysregulation leads to inflammatory and autoimmune diseases. We demonstrate that PCIF1 deficiency robustly enhances the poly(I:C)-induced type I IFN response, accompanied by augmented STAT1 activation and interferon-stimulated gene (ISG) expression. Mechanistically, PCIF1 suppresses IFNB1 transcription by attenuating IRF3 phosphorylation and nuclear translocation, as shown by increased nascent IFNB1 mRNA synthesis and promoter activity in PCIF1-deficient cells, without affecting the mRNA stability. Crucially, this suppressive function was independent of PCIF1’s canonical RNA methyltransferase activity, as both wild-type PCIF1 and a methyltransferase-inactive mutant effectively attenuated type I IFN induction. Collectively, our findings establish PCIF1 as a novel methyltransferase-independent suppressor of type I IFN responses, revealing its previously unrecognized non-catalytic function. This discovery offers critical insights into the multifaceted regulation of innate immunity and highlights PCIF1’s non-catalytic function as a promising therapeutic target for modulating antiviral responses and inflammatory diseases.